Project Studie CA209-511 (EUDRACT Number 2015-004920-67)

Basic data

Title:
Studie CA209-511 (EUDRACT Number 2015-004920-67)
Duration:
01/07/2016 to 28/02/2022
Abstract / short description:
Studie CA209-511: Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination with
Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination with Ipilimumab 3 mg/kg in
Subjects with Previously Untreated, Unresectable or Metastatic Melanoma
(CheckMate 511: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 511)

Involved staff

Managers

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Tampouri, Ioanna
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Spänkuch, Iris
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine

Funders

Help

will be deleted permanently. This cannot be undone.